US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

NANOBIOTIX SPON ADS EACH REP 1 ORD SHS

3.30

-0.0921-2.72%

Volume:23.79K

Turnover:80.27K

Market Cap:156.44M

PE:-2.21

High:3.48

Open:3.42

Low:3.30

Close:3.39

Loading ...

Overview Company News Filings

Leerink Partners Sticks to Its Buy Rating for Nanobiotix (NBTX)

Nanobiotix Says Potential Pancreatic Cancer Treatment Extends Survival in Phase 1 Study

MT Newswires Live

Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer

Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call

Voting Rights and Shares Capital of the Company

Nanobiotix price target lowered to $8 from $12 at Guggenheim

NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results

Nanobiotix SA expected to post a loss of 36 cents a share - Earnings Preview

NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025

Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC

NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference

Nanobiotix Sa : Leerink Partners Cuts Target Price to $9 From $11

THOMSON REUTERS

Nanobiotix amends global licensing agreement with Janssen Pharmaceutica

Nanobiotix files $200M mixed securities shelf

Nanobiotix files to sell 5.62M ordinary shares for holders

Nanobiotix downgraded to Neutral from Buy at UBS

UBS downgrades Nanobiotix (NBTX) to a Hold

Nanobiotix Sa : UBS Cuts to Neutral From Buy

THOMSON REUTERS

Is Nanobiotix (NBTX) the Best Nanotech Penny Stock to Invest In?

Nanobiotix Stock Gains as Dosing Begins in Mid-Stage NSCLC Study

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/NBTX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NBTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NBTX\",,,,,undefined,":{"symbol":"NBTX","market":"US","secType":"STK","nameCN":"NANOBIOTIX SPON ADS EACH REP 1 ORD SHS","latestPrice":3.3,"timestamp":1746648000000,"preClose":3.3921,"halted":0,"volume":23788,"delay":0,"floatShares":26214613,"shares":47404733,"eps":-1.492373,"marketStatus":"Not Yet Opened","change":-0.0921,"latestTime":"05-07 16:00:00 EDT","open":3.42,"high":3.475,"low":3.3,"amount":80269.692742,"amplitude":0.05159,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-1.492373,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1746691200000},"marketStatusCode":0,"adr":0,"adrRate":1,"listingDate":1607662800000,"exchange":"NASDAQ","adjPreClose":3.3921,"preHourTrading":{"tag":"盘前","latestPrice":3.43,"preClose":3.89,"latestTime":"09:29 EDT","volume":2882,"amount":9973.2598526,"timestamp":1746624570179},"volumeRatio":1.585444},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NBTX\",,,,,undefined,":{"symbol":"NBTX","floatShares":26214613,"roa":"-52.89%","roe":"--","lyrEps":-1.492373,"volumeRatio":1.585444,"shares":47404733,"dividePrice":0,"high":3.475,"amplitude":0.05159,"preClose":3.3921,"low":3.3,"week52Low":2.76,"pbRate":"-2.10","psRate":"-19.22","week52High":7.51,"institutionHeld":0,"latestPrice":3.3,"eps":-1.492373,"divideRate":0,"volume":23788,"delay":0,"ttmEps":-1.492373,"open":3.42,"prevYearClose":2.87,"prevWeekClose":3.341,"prevMonthClose":3.39,"prevQuarterClose":3.58,"fiveDayClose":3.39,"twentyDayClose":3.02,"sixtyDayClose":3.935},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NBTX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2533640214","title":"Leerink Partners Sticks to Its Buy Rating for Nanobiotix (NBTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2533640214","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533640214?lang=en_us&edition=fundamental","pubTime":"2025-05-07 13:17","pubTimestamp":1746595072,"startTime":"0","endTime":"0","summary":"In a report released on May 5, Jonathan Chang from Leerink Partners reiterated a Buy rating on Nanobiotix (NBTX – Research Report). The company’s s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/leerink-partners-sticks-to-its-buy-rating-for-nanobiotix-nbtx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/leerink-partners-sticks-to-its-buy-rating-for-nanobiotix-nbtx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NBTX"],"gpt_icon":0},{"id":"2533303768","title":"Nanobiotix Says Potential Pancreatic Cancer Treatment Extends Survival in Phase 1 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2533303768","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533303768?lang=en_us&edition=fundamental","pubTime":"2025-05-05 16:09","pubTimestamp":1746432577,"startTime":"0","endTime":"0","summary":"Nanobiotix  said Monday its JNJ-1900 drug candidate showed a median overall survival of 23 months for certain patients with pancreatic cancer in a phase 1 study.A historical review of 144 patients with locally advanced pancreatic cancer treated at the same center showed a median overall survival of 19.2 months, the company said.The drug, jointly developed with Johnson & Johnson  subsidiary Janssen Pharmaceutica, also showed a favorable safety profile, Nanobiotix said.The company added that the results prompted investigators to recommend further evaluation in a randomized study. The US Food and Drug Administration has also cleared researchers to expand the study to include a new cohort that has already recruited and dosed its first patient, the company said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0640476718.USD","LU0289739699.SGD","LU2129689605.HKD","LU0122379950.USD","IE00B7SZLL34.SGD","IE00BDGV0183.EUR","IE00BBT3K403.USD","LU1066053197.SGD","LU1244550494.USD","LU1935042991.SGD","LU1244550577.SGD","LU0889566641.SGD","LU2505996681.GBP","BK4504","IE00BSNM7G36.USD","LU1244550221.USD","LU2430703095.HKD","LU1032955483.USD","LU1066051811.HKD","LU1718418525.SGD","LU1914381329.SGD","LU2430703251.USD","IE00BN8TJ469.HKD","LU1506573853.SGD","LU0345770993.USD","LU1585245621.USD","LU0234572021.USD","LU0203347892.USD","LU0795875169.SGD","LU2430703178.SGD","NBTX","LU0114720955.EUR","LU1894683348.USD","IE0002270589.USD","BK4559","LU1894683264.USD","LU1196500208.SGD","BK4534","LU0985320562.USD","BK4588","IE00BLSP4452.SGD","LU1032466523.USD","IE00BJT1NW94.SGD","LU0345769631.USD","LU1162221912.USD","BK4550","JNJ","LU0058720904.USD","LU1732799900.SGD","LU1074936037.SGD"],"gpt_icon":0},{"id":"2533216372","title":"Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2533216372","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533216372?lang=en_us&edition=fundamental","pubTime":"2025-05-05 14:00","pubTimestamp":1746424800,"startTime":"0","endTime":"0","summary":"Results demonstrated favorable safety, injection feasibility, and encouraging oncologic outcomes in patients  with locally advanced or borderline resectable pancreatic cancer. Median Overall Survival of 23 months from date of diagnosis [95% CI; 17 months – not reached]. Median Local Progression-Free Survival of 13.3 months from completion of radiation. Notable findings observed in exploratory biomarker analyses include:. An association between increased circulating tumor mutational burden  and LPFS and OS. CA19-9 normalization in 59% of patients in the study, and an association between CA19-9 normalization and OS. First patient injected in a new cohort that adds standard-of-care concurrent chemotherapy  to radiotherapy-activated JNJ-1900  and recruitment is ongoing. Investigators concluded that these results support further evaluation in a randomized study. “Patients with locally advanced or borderline resectable pancreatic cancer face a particularly urgent unmet need for therapeutic i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nanobiotix-announces-full-results-completed-060000624.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4534","IE00B1BXHZ80.USD","BK4007","IE00BSNM7G36.USD","LU2347655156.SGD","BK4504","IE00BBT3K403.USD","BK4568","LU0234572021.USD","LU2505996509.AUD","LU1280957306.USD","IE00BLSP4452.SGD","LU0345770993.USD","IE00BLSP4239.USD","IE00B19Z3B42.SGD","LU2602419157.SGD","IE00B19Z3581.USD","LU1674673428.USD","LU1894683264.USD","LU0795875169.SGD","LU0203347892.USD","LU1244550221.USD","IE00B4R5TH58.HKD","BK4559","LU2430703095.HKD","IE000M9KFDE8.USD","IE00BDGV0183.EUR","LU1032466523.USD","SG9999001440.SGD","BK4533","IE00B42XCP33.USD","LU2505996681.GBP","IE00BN8TJ469.HKD","LU0466842654.USD","NBTX","LU1066053197.SGD","LU0345769128.USD","LU1244550494.USD","IE0002141913.USD","LU2112291526.USD","LU2468319806.SGD","JNJ","LU1221951046.USD","LU1267930813.SGD","LU1732799900.SGD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LU1066051225.USD","LU2430703178.SGD","LU2089984988.USD"],"gpt_icon":0},{"id":"2531720867","title":"Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2531720867","media":"GlobeNewswire","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531720867?lang=en_us&edition=fundamental","pubTime":"2025-04-30 14:00","pubTimestamp":1745992800,"startTime":"0","endTime":"0","summary":"Full results from the completed dose escalation part and dose expansion parts of a Phase 1 study evaluating JNJ-1900  after induction chemotherapy for patients with locally advanced or borderline resectable pancreatic cancer to be presented by Principal Investigator Eugene Koay, MD, at ESTRO 2025 on Sunday, May 4th at 11:00 AM EDT / 5:00 PM CEST. Nanobiotix will host an event on Monday, May 5th at 8:00AM EDT / 2:00PM CEST to review the presented results. PARIS andCAMBRIDGE, Mass., April 30, 2025  -- NANOBIOTIX , a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the presentation of full results from the completed dose escalation and dose expansion parts of a Phase 1 study evaluating JNJ-1900  in patients with locally advanced or borderline resectable pancreatic cancer. The study, conducted by The University of Texas MD Anderson Cancer Center","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nanobiotix-announces-presentation-full-results-060000184.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0985320562.USD","BK4585","LU0912757837.SGD","NBTX","LU2089984988.USD","IE00BLSP4239.USD","LU0345769631.USD","LU0234572021.USD","IE00BSNM7G36.USD","LU1894683348.USD","LU2602419157.SGD","LU0098860793.USD","LU1261432733.SGD","BK4504","LU0203345920.USD","LU1162221912.USD","LU1023059063.AUD","BK4533","LU1732800096.USD","LU1914381329.SGD","LU2112291526.USD","LU0795875169.SGD","LU1221951129.SGD","IE00B1BXHZ80.USD","LU1778281490.HKD","IE00B4R5TH58.HKD","LU1267930813.SGD","JNJ","BK4568","IE000M9KFDE8.USD","LU0203347892.USD","LU1244550577.SGD","LU1244550221.USD","LU2468319806.SGD","LU0466842654.USD","IE00BDGV0183.EUR","IE00B3T34201.USD","LU1032955483.USD","LU1196500208.SGD","LU2430703095.HKD","LU2505996509.AUD","LU2347655156.SGD","IE0034235303.USD","LU2430703251.USD","LU1066053197.SGD","LU1280957306.USD","LU0345770308.USD","IE0009355771.USD","LU1929549753.HKD","IE00BLSP4452.SGD"],"gpt_icon":0},{"id":"2527214957","title":"Voting Rights and Shares Capital of the Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2527214957","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527214957?lang=en_us&edition=fundamental","pubTime":"2025-04-15 04:15","pubTimestamp":1744661700,"startTime":"0","endTime":"0","summary":"In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority . Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts  amongst other locations.Nanobiotix is the owner of more than 25 patent families associated with three  nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.2 The total number of exercisable at a shareholders’ meeting  voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed.2025-04-14 -- NBTX -- Voting Rights + Shares Capital -- FINAL","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/voting-rights-shares-capital-company-201500281.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NBTX","BK4139"],"gpt_icon":0},{"id":"2524080572","title":"Nanobiotix price target lowered to $8 from $12 at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2524080572","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524080572?lang=en_us&edition=fundamental","pubTime":"2025-04-04 19:11","pubTimestamp":1743765076,"startTime":"0","endTime":"0","summary":"Guggenheim lowered the firm’s price target on Nanobiotix (NBTX) to $8 from $12 and keeps a Buy rating on the shares. After the company reported FY2...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nanobiotix-price-target-lowered-to-8-from-12-at-guggenheim?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nanobiotix-price-target-lowered-to-8-from-12-at-guggenheim?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NBTX","BK4139"],"gpt_icon":0},{"id":"2524844579","title":"NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2524844579","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524844579?lang=en_us&edition=fundamental","pubTime":"2025-04-03 04:15","pubTimestamp":1743624900,"startTime":"0","endTime":"0","summary":"Global development program for JNJ-1900 (NBTXR3) proceeding as planned, with opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck cancer and lu","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/02/3054710/0/en/NANOBIOTIX-Provides-Business-Update-and-Reports-Full-Year-2024-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B19Z3B42.SGD","JNJ","IE00B7SZLL34.SGD","IE00B3T34201.USD","LU1929549753.HKD","LU2089984988.USD","LU2347655156.SGD","LU1244550494.USD","LU1066051811.HKD","IE00BDGV0183.EUR","LU0795875169.SGD","LU1059921491.USD","LU2129689514.USD","BK4504","BK4532","SG9999002232.USD","IE00B2B36J28.USD","LU0466842654.USD","LU1023059063.AUD","SG9999001440.SGD","LU1244550577.SGD","BK4534","LU1585245621.USD","LU0912757837.SGD","LU0345770993.USD","LU0320765646.SGD","LU2430703251.USD","LU1732799900.SGD","NBTX","LU1221951129.SGD","IE00B3PB1722.GBP","IE00BGHQF631.EUR","IE00BVYPNV92.GBP","LU0058720904.USD","LU1718418525.SGD","LU0098860793.USD","LU0795875086.SGD","LU1221951046.USD","LU2468319806.SGD","LU0203347892.USD","IE0002270589.USD","LU0792757196.USD","IE0002141913.USD","LU1674673691.USD","LU2112291526.USD","IE00BFTCPJ56.SGD","LU0889566641.SGD","LU2133065610.SGD","LU0345769128.USD"],"gpt_icon":0},{"id":"2523940465","title":"Nanobiotix SA  expected to post a loss of 36 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2523940465","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523940465?lang=en_us&edition=fundamental","pubTime":"2025-03-31 22:02","pubTimestamp":1743429777,"startTime":"0","endTime":"0","summary":"Nanobiotix SA  expected to post a loss of36cents a share - Earnings Preview Nanobiotix SA NBTX.OQ, NBTX.O is expected to report results on April 2 for the period ending June 30 2024LSEG's mean analyst","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nL5N3QE136:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBTX"],"gpt_icon":0},{"id":"2523965815","title":"NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2523965815","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523965815?lang=en_us&edition=fundamental","pubTime":"2025-03-31 14:00","pubTimestamp":1743400800,"startTime":"0","endTime":"0","summary":"Conference call and webcast scheduled for Thursday, April 3, 2025, at 8:00 am EDT / 2:00 pm CEST. PARIS and CAMBRIDGE, Mass., March 31, 2025  -- NANOBIOTIX , a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2024, on Wednesday, April 2, 2025, after the close of the U.S. market.This release will be followed by a conference call and webcast on Thursday, April 3, 2025, at 8:00 AM EDT / 2:00 PM CEST, prior to the open of the U.S. market. During the call, Laurent Levy, chief executive officer, and Bart van Rhijn, chief financial and business officer, will briefly review the Company’s year-end results and provide an update on business activities for the fourth quarter and full year of 2024 before taking questions from participants.France – HARDYCaroline Hardy+33","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nanobiotix-announce-fourth-quarter-full-060000618.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NBTX","BK4139"],"gpt_icon":0},{"id":"2522531667","title":"Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2522531667","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522531667?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:15","pubTimestamp":1743106500,"startTime":"0","endTime":"0","summary":"Data show favorable safety and confirm injection feasibility in 12 patients with locally advanced NSCLC amenable to re-irradiation for whom prior lines of therapy have failedA preliminary review of su","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/27/3051020/0/en/Nanobiotix-Announces-First-Data-From-the-Completed-Dose-Escalation-Part-of-a-Phase-1-Study-Evaluating-NBTXR3-JNJ-1900-as-a-2L-Therapy-for-Patients-With-Locally-Advanced-NSCLC.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","IE00BFTCPJ56.SGD","LU0345770308.USD","LU0122379950.USD","LU1066053197.SGD","BK4568","LU1894683264.USD","BK4532","BK4581","IE00B1BXHZ80.USD","JNJ","LU0889566641.SGD","LU0345769631.USD","IE00BGHQF631.EUR","LU0640476718.USD","LU0882574055.USD","LU1221951046.USD","LU2129689514.USD","LU1162221912.USD","LU2430703251.USD","IE00B7SZL793.SGD","LU0098860793.USD","BK4559","SG9999002232.USD","BK4550","LU0345770993.USD","LU1059921491.USD","LU1674673428.USD","LU1929549753.HKD","LU1244550494.USD","IE00BJJMRZ35.SGD","LU2592432038.USD","BK4157","LU1732799900.SGD","IE00B4R5TH58.HKD","BK4592","LU1506573853.SGD","NBTX","IE00BSNM7G36.USD","IE00B7SZLL34.SGD","IE00B3PB1722.GBP","IE00BVYPNV92.GBP","LU2112291526.USD","AEIS","LU1032466523.USD","LU1074936037.SGD","LU1267930813.SGD","IE00BJT1NW94.SGD","LU2602419157.SGD","LU0114720955.EUR"],"gpt_icon":0},{"id":"2521993104","title":"NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2521993104","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521993104?lang=en_us&edition=fundamental","pubTime":"2025-03-21 04:15","pubTimestamp":1742501700,"startTime":"0","endTime":"0","summary":"Data evaluating safety and early signals of efficacy including updated local PFS from the completed dose escalation part of a Phase 1 study of re-irradiation with JNJ-1900 (NBTXR3) for patients with u","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/20/3046726/0/en/NANOBIOTIX-Announces-Presentation-of-Data-From-Two-Phase-1-Studies-Evaluating-JNJ-1900-NBTXR3-at-the-European-Lung-Cancer-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4592","LU2347655156.SGD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","LU0882574055.USD","LU1221951046.USD","LU2133065610.SGD","IE00B19Z3B42.SGD","LU0795875086.SGD","LU0345770993.USD","LU0345769128.USD","LU1057294990.SGD","NBTX","IE00B7SZLL34.SGD","BK4139","LU1280957306.USD","BK4581","LU0792757196.USD","SG9999002232.USD","LU1196500208.SGD","LU1162221912.USD","LU0058720904.USD","LU1674673691.USD","LU0345769631.USD","LU1032955483.USD","IE00B42XCP33.USD","LU2129689605.HKD","LU1023059063.AUD","LU1430594728.SGD","LU2089984988.USD","LU0203345920.USD","BK4533","LU1778281490.HKD","LU1221951129.SGD","LU0098860793.USD","LU0640476718.USD","LU1244550577.SGD","LU1732799900.SGD","LU0234572021.USD","LU0234570918.USD","BK4007","LU2112291526.USD","LU1066051498.USD","SG9999002224.SGD","JNJ","IE0002141913.USD","IE0034235303.USD","LU1267930813.SGD","LU1894683348.USD","IE000M9KFDE8.USD"],"gpt_icon":0},{"id":"2520608526","title":"Nanobiotix Sa : Leerink Partners Cuts Target Price to $9 From $11","url":"https://stock-news.laohu8.com/highlight/detail?id=2520608526","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520608526?lang=en_us&edition=fundamental","pubTime":"2025-03-18 21:54","pubTimestamp":1742306078,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nFWN3Q11BI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NBTX","BK4139"],"gpt_icon":0},{"id":"2520685770","title":"Nanobiotix amends global licensing agreement with Janssen Pharmaceutica","url":"https://stock-news.laohu8.com/highlight/detail?id=2520685770","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520685770?lang=en_us&edition=fundamental","pubTime":"2025-03-18 04:25","pubTimestamp":1742243154,"startTime":"0","endTime":"0","summary":"Nanobiotix (NBTX) announced the execution of another step in its financial strategy through the amendment of the company’s global licensing agreeme...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nanobiotix-amends-global-licensing-agreement-with-janssen-pharmaceutica?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nanobiotix-amends-global-licensing-agreement-with-janssen-pharmaceutica?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NBTX","BK4139"],"gpt_icon":0},{"id":"2517211648","title":"Nanobiotix files $200M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2517211648","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517211648?lang=en_us&edition=fundamental","pubTime":"2025-03-07 05:56","pubTimestamp":1741298179,"startTime":"0","endTime":"0","summary":"16:50 EST Nanobiotix (NBTX) files $200M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breakin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nanobiotix-files-200m-mixed-securities-shelf?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nanobiotix-files-200m-mixed-securities-shelf?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NBTX"],"gpt_icon":0},{"id":"2517161051","title":"Nanobiotix files to sell 5.62M ordinary shares for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2517161051","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517161051?lang=en_us&edition=fundamental","pubTime":"2025-03-07 05:56","pubTimestamp":1741298162,"startTime":"0","endTime":"0","summary":"16:54 EST Nanobiotix (NBTX) files to sell 5.62M ordinary shares for holders Published first on TheFly – the ultimate source for real-time, market-m...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nanobiotix-files-to-sell-5-62m-ordinary-shares-for-holders?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nanobiotix-files-to-sell-5-62m-ordinary-shares-for-holders?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NBTX"],"gpt_icon":0},{"id":"2512944040","title":"Nanobiotix downgraded to Neutral from Buy at UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2512944040","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512944040?lang=en_us&edition=fundamental","pubTime":"2025-02-17 20:20","pubTimestamp":1739794805,"startTime":"0","endTime":"0","summary":"UBS downgraded Nanobiotix (NBTX) to Neutral from Buy with a price target of $3.50, down from $12, as a new analyst assumed coverage of the stock. T...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nanobiotix-downgraded-to-neutral-from-buy-at-ubs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nanobiotix-downgraded-to-neutral-from-buy-at-ubs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NBTX","BK4139"],"gpt_icon":0},{"id":"2512391096","title":"UBS downgrades Nanobiotix (NBTX) to a Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2512391096","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512391096?lang=en_us&edition=fundamental","pubTime":"2025-02-17 17:37","pubTimestamp":1739785079,"startTime":"0","endTime":"0","summary":"UBS analyst David Dai downgraded Nanobiotix (NBTX – Research Report) to a Hold today and set a price target of $3.50. The company’s shares closed l...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/ubs-downgrades-nanobiotix-nbtx-to-a-hold?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/ubs-downgrades-nanobiotix-nbtx-to-a-hold?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NBTX"],"gpt_icon":0},{"id":"2512912243","title":"Nanobiotix Sa : UBS Cuts to Neutral From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2512912243","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512912243?lang=en_us&edition=fundamental","pubTime":"2025-02-17 17:06","pubTimestamp":1739783180,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250217:nAZN3DMQAV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NBTX"],"gpt_icon":0},{"id":"2511462576","title":"Is Nanobiotix (NBTX) the Best Nanotech Penny Stock to Invest In?","url":"https://stock-news.laohu8.com/highlight/detail?id=2511462576","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511462576?lang=en_us&edition=fundamental","pubTime":"2025-02-15 00:30","pubTimestamp":1739550618,"startTime":"0","endTime":"0","summary":"Nanotech involves working with tiny particles which are about the size of molecules. This field is being used to improve products in many different industries, like electronics, medicine, and energy. By manipulating matter at this tiny scale, materials and devices with special properties can be made. The global nanotech market was valued at $3.69 billion in 2022 and is projected to grow at a 33.1% CAGR from 2023 to 2030, as reported by Grand View Research. This is driven by the increased use in medical diagnostics and imaging, technological advancements, substantial R&D funding, and the creation of advanced materials for healthcare, electronics, aerospace, textiles, transportation, manufacturing, and agriculture.While the nanotech industry as a whole holds promise, it is still in its early innings and many companies are in the small-cap territory.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nanobiotix-nbtx-best-nanotech-penny-163018629.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TQQQ","SQQQ","TSYW.SI","MNQmain","USAW.SI","BK4139",".IXIC","QID","QLD","NQmain","PSQ","NBTX","USJW.SI","NVIW.SI"],"gpt_icon":1},{"id":"2505204653","title":"Nanobiotix Stock Gains as Dosing Begins in Mid-Stage NSCLC Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2505204653","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505204653?lang=en_us&edition=fundamental","pubTime":"2025-01-21 23:43","pubTimestamp":1737474180,"startTime":"0","endTime":"0","summary":"NanobiotixNBTX shares were up around 13% during the pre-market hours on Tuesday after the company announced that it has initiated dosing in a mid-stage study evaluating a potential first-in-class radioenhancer, JNJ-1900 , to treat lung cancer patients. The candidate was added to Nanobiotix’s pipeline following a licensing deal for the global co-development and commercialization with pharma bigwig, Johnson & Johnson JNJ, in 2023.The company stated that it has dosed the first patient with JNJ-1900 in the phase II CONVERGE study to treat patients with Stage 3 unresectable non-small cell lung cancer . The eligibility criteria for this study include NSCLC patients receiving standard-of-care chemoradiation followed by consolidation immunotherapy with AstraZeneca’s Imfinzi . Per the global licensing agreement with Nanobiotix, Johnson & Johnson is responsible for funding the CONVERGE study.Nanobiotix’s pipeline comprises only JNJ-1900, which is being evaluated across multiple solid tumor indic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nanobiotix-stock-gains-dosing-begins-154300753.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0122379950.USD","LU0795875169.SGD","LU1196500208.SGD","SG9999002224.SGD","LU1066051498.USD","LU0882574055.USD","LU0289739699.SGD","LU1778281490.HKD","LU1929549753.HKD","IE00BVYPNW00.USD","LU0345769128.USD","LU1023059063.AUD","LU1244550494.USD","LU2347655156.SGD","IE00BGHQF631.EUR","BK4568","LU2602419157.SGD","NBTX","IE00B3PB1722.GBP","LU0889566641.SGD","IE0002270589.USD","BK4532","IE0034235303.USD","JNJ","LU1244550221.USD","LU1732799900.SGD","IE00B2B36J28.USD","LU1935042991.SGD","BMRN","LU1674673428.USD","LU1032955483.USD","BK4588","LU1066051811.HKD","LU0203345920.USD","LU1032466523.USD","CSTL","LU1732800096.USD","LU1894683348.USD","SSI","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","LU0640476718.USD","BK4139","LU0234572021.USD","IE00BDGV0183.EUR","LU0320765646.SGD","BK4550","IE00B42XCP33.USD","LU1430594728.SGD","LU0792757196.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":28,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NBTX\",params:#limit:5,,,undefined,":[{"date":"2025-04-02","symbol":"NBTX","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2024/12","expectedEps":null,"defaultRemindTime":1743624000000,"name":null,"time":"Post Market","dateTimestamp":1743566400000,"actualEps":null},{"date":"2024-11-12","symbol":"NBTX","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1731402000000,"name":null,"time":"Pre-Market","dateTimestamp":1731387600000,"actualEps":null},{"market":"US","date":"2024-09-18","symbol":"NBTX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1726632000000,"reportTimeType":"post","actualEps":null},{"date":"2024-05-22","symbol":"NBTX","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2024/03","expectedEps":null,"defaultRemindTime":1716364800000,"name":null,"time":"Pre-Market","dateTimestamp":1716350400000,"actualEps":null},{"date":"2024-04-24","symbol":"NBTX","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1713988800000,"name":null,"time":"Post Market","dateTimestamp":1713931200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NBTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NBTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.7143,"buy":0.1429,"hold":0.1429,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.7143,"analysts":7,"updateTime":1743566400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NBTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NBTX","date":"2025-05-06","current":-2.09777,"percent":0.958237,"low":-8.05756,"twenty":-5.745151,"median":-4.91141,"eighty":-4.22993,"high":-1.979488,"avg":-4.974184,"sd":1.135856,"marketCap":162193904.9},"quantilePoints":[{"date":"2023-07-14","current":-3.501201,"twenty":-3.535419,"median":-3.522587,"eighty":-3.509755,"marketCap":223541537.94},{"date":"2023-07-21","current":-4.607165,"twenty":-4.211217,"median":-3.916701,"eighty":-3.561082,"marketCap":292908275.75},{"date":"2023-07-28","current":-4.472424,"twenty":-4.908851,"median":-4.368706,"eighty":-3.686954,"marketCap":280373135.51},{"date":"2023-08-04","current":-4.167347,"twenty":-4.820211,"median":-4.216168,"eighty":-3.916701,"marketCap":260275527.21},{"date":"2023-08-11","current":-5.137491,"twenty":-4.838516,"median":-4.448017,"eighty":-3.996135,"marketCap":322810760.08},{"date":"2023-08-18","current":-4.740891,"twenty":-4.85682,"median":-4.484627,"eighty":-4.088027,"marketCap":294164220.6},{"date":"2023-08-25","current":-5.979502,"twenty":-5.11432,"median":-4.740891,"eighty":-4.136839,"marketCap":369410580.53},{"date":"2023-09-01","current":-5.167998,"twenty":-5.222912,"median":-4.829363,"eighty":-4.167347,"marketCap":319726459.87},{"date":"2023-09-08","current":-5.481134,"twenty":-5.430364,"median":-4.85377,"eighty":-4.24546,"marketCap":334563278.76},{"date":"2023-09-15","current":-5.474962,"twenty":-5.525576,"median":-5.003257,"eighty":-4.299143,"marketCap":333117121.07},{"date":"2023-09-22","current":-5.148636,"twenty":-5.489775,"median":-5.033765,"eighty":-4.41995,"marketCap":313162034.55},{"date":"2023-09-29","current":-5.106809,"twenty":-5.476196,"median":-5.064272,"eighty":-4.452899,"marketCap":317195243.03},{"date":"2023-10-06","current":-3.91317,"twenty":-5.458808,"median":-5.082465,"eighty":-4.440723,"marketCap":242185565.38},{"date":"2023-10-13","current":-3.790114,"twenty":-5.430364,"median":-5.003257,"eighty":-4.161245,"marketCap":235064644.44},{"date":"2023-10-20","current":-3.53785,"twenty":-5.37545,"median":-4.917201,"eighty":-3.980248,"marketCap":219952860.92},{"date":"2023-10-27","current":-3.593225,"twenty":-5.352028,"median":-4.890347,"eighty":-3.913876,"marketCap":222431066.76},{"date":"2023-11-03","current":-3.568614,"twenty":-5.301288,"median":-4.850719,"eighty":-3.84795,"marketCap":222689835.46},{"date":"2023-11-10","current":-4.213554,"twenty":-5.270695,"median":-4.81716,"eighty":-3.860256,"marketCap":265329783.61},{"date":"2023-11-17","current":-4.362915,"twenty":-5.238319,"median":-4.607165,"eighty":-3.876253,"marketCap":278584883.77},{"date":"2023-11-24","current":-4.166387,"twenty":-5.222912,"median":-4.472424,"eighty":-3.900864,"marketCap":267080431.84},{"date":"2023-12-01","current":-4.024888,"twenty":-5.218195,"median":-4.451068,"eighty":-3.91317,"marketCap":258037914.71},{"date":"2023-12-08","current":-4.087358,"twenty":-5.173999,"median":-4.362915,"eighty":-3.916701,"marketCap":259215849.61},{"date":"2023-12-15","current":-4.34382,"twenty":-5.167998,"median":-4.350062,"eighty":-3.926624,"marketCap":280750695.99},{"date":"2023-12-22","current":-4.61631,"twenty":-5.148636,"median":-4.362915,"eighty":-3.938415,"marketCap":298296767.07},{"date":"2023-12-29","current":-5.32158,"twenty":-5.156381,"median":-4.395914,"eighty":-3.945691,"marketCap":346498043.86},{"date":"2024-01-05","current":-5.682229,"twenty":-5.209356,"median":-4.411545,"eighty":-3.95755,"marketCap":366047647.12},{"date":"2024-01-12","current":-5.618114,"twenty":-5.287183,"median":-4.459615,"eighty":-3.987504,"marketCap":361560742.28},{"date":"2024-01-19","current":-5.409739,"twenty":-5.363247,"median":-4.484627,"eighty":-3.995192,"marketCap":345502680.36},{"date":"2024-01-26","current":-5.746345,"twenty":-5.441796,"median":-4.512123,"eighty":-3.996135,"marketCap":366085807.95},{"date":"2024-02-02","current":-5.562013,"twenty":-5.524341,"median":-4.6786,"eighty":-4.024888,"marketCap":354688432.41},{"date":"2024-02-09","current":-5.545984,"twenty":-5.530514,"median":-4.814109,"eighty":-4.024888,"marketCap":350925266.95},{"date":"2024-02-16","current":-5.545984,"twenty":-5.545984,"median":-4.844618,"eighty":-4.063315,"marketCap":350736495.97},{"date":"2024-02-23","current":-5.001003,"twenty":-5.545984,"median":-4.864912,"eighty":-4.081021,"marketCap":317981557.6},{"date":"2024-03-01","current":-4.76057,"twenty":-5.545984,"median":-4.85682,"eighty":-4.086976,"marketCap":302497661.87},{"date":"2024-03-08","current":-4.720498,"twenty":-5.539572,"median":-4.839615,"eighty":-4.087893,"marketCap":303262323.5},{"date":"2024-03-15","current":-4.448007,"twenty":-5.532005,"median":-4.820211,"eighty":-4.093904,"marketCap":284791651.24},{"date":"2024-03-22","current":-4.624325,"twenty":-5.530067,"median":-4.776599,"eighty":-4.108163,"marketCap":295180454.99},{"date":"2024-03-28","current":-4.568224,"twenty":-5.526587,"median":-4.746723,"eighty":-4.116194,"marketCap":290056056.38},{"date":"2024-04-05","current":-4.576238,"twenty":-5.498417,"median":-4.720498,"eighty":-4.124016,"marketCap":292206179.67},{"date":"2024-04-12","current":-4.19956,"twenty":-5.477431,"median":-4.692448,"eighty":-4.1321,"marketCap":264391924.6},{"date":"2024-04-19","current":-4.207575,"twenty":-5.462847,"median":-4.640354,"eighty":-4.136281,"marketCap":263738379.19},{"date":"2024-04-26","current":-6.467408,"twenty":-5.477431,"median":-4.63234,"eighty":-4.150428,"marketCap":275046699.52},{"date":"2024-05-03","current":-6.97768,"twenty":-5.533496,"median":-4.68844,"eighty":-4.161892,"marketCap":296366656.68},{"date":"2024-05-10","current":-7.559154,"twenty":-5.552396,"median":-4.712483,"eighty":-4.16523,"marketCap":323347060.66},{"date":"2024-05-17","current":-8.027893,"twenty":-5.579986,"median":-4.740891,"eighty":-4.166963,"marketCap":346421016.3},{"date":"2024-05-24","current":-7.262484,"twenty":-5.611631,"median":-4.776599,"eighty":-4.16744,"marketCap":312069060.5},{"date":"2024-05-31","current":-7.701555,"twenty":-5.672612,"median":-4.81716,"eighty":-4.178722,"marketCap":331546033.4},{"date":"2024-06-07","current":-6.236005,"twenty":-5.710545,"median":-4.838516,"eighty":-4.197156,"marketCap":269389997.82},{"date":"2024-06-14","current":-5.007791,"twenty":-5.743958,"median":-4.85377,"eighty":-4.202043,"marketCap":214003558.67},{"date":"2024-06-21","current":-4.701628,"twenty":-5.735439,"median":-4.85377,"eighty":-4.206129,"marketCap":200015660.09},{"date":"2024-06-28","current":-5.280728,"twenty":-5.730501,"median":-4.85682,"eighty":-4.206491,"marketCap":224435161.12},{"date":"2024-07-05","current":-5.791,"twenty":-5.768785,"median":-4.872772,"eighty":-4.208771,"marketCap":248543463.78},{"date":"2024-07-12","current":-5.948876,"twenty":-5.790083,"median":-4.896815,"eighty":-4.218271,"marketCap":256734839.66},{"date":"2024-07-15","current":-5.803199,"twenty":-5.798319,"median":-4.896815,"eighty":-4.222987,"marketCap":251459290.55},{"date":"2024-08-02","current":-5.528562,"twenty":-5.79588,"median":-4.902252,"eighty":-4.227704,"marketCap":236716903.58},{"date":"2024-08-09","current":-5.218103,"twenty":-5.78825,"median":-4.912857,"eighty":-4.250846,"marketCap":226007727.47},{"date":"2024-08-16","current":-5.385273,"twenty":-5.782047,"median":-4.966007,"eighty":-4.262987,"marketCap":234836714.63},{"date":"2024-08-23","current":-5.624088,"twenty":-5.773886,"median":-5.003257,"eighty":-4.271861,"marketCap":248002101.52},{"date":"2024-08-30","current":-5.951264,"twenty":-5.78825,"median":-5.02715,"eighty":-4.280804,"marketCap":261702690.52},{"date":"2024-09-06","current":-5.318405,"twenty":-5.783503,"median":-5.082465,"eighty":-4.2933,"marketCap":234080576.5},{"date":"2024-09-13","current":-5.20855,"twenty":-5.775635,"median":-5.106809,"eighty":-4.309314,"marketCap":228183011.48},{"date":"2024-09-20","current":-6.387098,"twenty":-5.783503,"median":-5.121967,"eighty":-4.313357,"marketCap":238132484.96},{"date":"2024-09-27","current":-6.610859,"twenty":-5.823638,"median":-5.137491,"eighty":-4.320566,"marketCap":247329041.02},{"date":"2024-10-04","current":-6.622189,"twenty":-5.911442,"median":-5.170998,"eighty":-4.334203,"marketCap":244150821.68},{"date":"2024-10-11","current":-6.262472,"twenty":-5.933402,"median":-5.182281,"eighty":-4.345169,"marketCap":229021882.44},{"date":"2024-10-18","current":-6.344612,"twenty":-5.96344,"median":-5.207356,"eighty":-4.349488,"marketCap":229965569.03},{"date":"2024-10-25","current":-5.891426,"twenty":-6.017528,"median":-5.218103,"eighty":-4.356925,"marketCap":213008953.34},{"date":"2024-10-31","current":-5.57986,"twenty":-5.977675,"median":-5.222912,"eighty":-4.362915,"marketCap":202795491.86},{"date":"2024-11-08","current":-5.599687,"twenty":-5.970096,"median":-5.248048,"eighty":-4.36711,"marketCap":202177018.66},{"date":"2024-11-15","current":-5.200316,"twenty":-5.966221,"median":-5.253925,"eighty":-4.388701,"marketCap":184162271.48},{"date":"2024-11-22","current":-4.956728,"twenty":-5.95433,"median":-5.236108,"eighty":-4.408657,"marketCap":174044440.37},{"date":"2024-11-29","current":-4.2203,"twenty":-5.951264,"median":-5.220553,"eighty":-4.390245,"marketCap":149030598.16},{"date":"2024-12-06","current":-4.381748,"twenty":-5.948876,"median":-5.208813,"eighty":-4.362915,"marketCap":155026152.63},{"date":"2024-12-13","current":-4.565855,"twenty":-5.948074,"median":-5.207356,"eighty":-4.362915,"marketCap":160302977.76},{"date":"2024-12-20","current":-4.534698,"twenty":-5.933402,"median":-5.191833,"eighty":-4.378915,"marketCap":157589239},{"date":"2024-12-27","current":-4.342094,"twenty":-5.933402,"median":-5.179892,"eighty":-4.351783,"marketCap":151367330.76},{"date":"2025-01-03","current":-4.262786,"twenty":-5.933402,"median":-5.167998,"eighty":-4.34313,"marketCap":146331910.57},{"date":"2025-01-10","current":-4.206138,"twenty":-5.933402,"median":-5.137491,"eighty":-4.320566,"marketCap":144937262.71},{"date":"2025-01-17","current":-4.296775,"twenty":-5.9259,"median":-5.121967,"eighty":-4.288937,"marketCap":148060488.98},{"date":"2025-01-24","current":-4.789616,"twenty":-5.913045,"median":-5.106809,"eighty":-4.298956,"marketCap":166915988.55},{"date":"2025-01-31","current":-4.956728,"twenty":-5.905291,"median":-5.100657,"eighty":-4.308498,"marketCap":172955868.86},{"date":"2025-02-07","current":-5.480725,"twenty":-5.898224,"median":-5.082771,"eighty":-4.312559,"marketCap":190346872.8},{"date":"2025-02-14","current":-5.509049,"twenty":-5.889516,"median":-5.104251,"eighty":-4.318157,"marketCap":192589463.19},{"date":"2025-02-21","current":-5.101181,"twenty":-5.881878,"median":-5.101181,"eighty":-4.327791,"marketCap":178685483.47},{"date":"2025-02-28","current":-4.905745,"twenty":-5.862201,"median":-5.100919,"eighty":-4.342094,"marketCap":170874084.29},{"date":"2025-03-07","current":-4.367586,"twenty":-5.827081,"median":-5.070025,"eighty":-4.34382,"marketCap":158323799},{"date":"2025-03-14","current":-4.174981,"twenty":-5.818474,"median":-5.054777,"eighty":-4.311762,"marketCap":151818741.99},{"date":"2025-03-21","current":-4.803778,"twenty":-5.803199,"median":-5.038868,"eighty":-4.311762,"marketCap":174475753.04},{"date":"2025-03-28","current":-4.860426,"twenty":-5.791,"median":-5.008404,"eighty":-4.315749,"marketCap":175618569.73},{"date":"2025-04-04","current":-2.056719,"twenty":-5.786417,"median":-5.001003,"eighty":-4.311762,"marketCap":155112231.57},{"date":"2025-04-11","current":-2.052545,"twenty":-5.779133,"median":-4.956728,"eighty":-4.282613,"marketCap":156407518.17},{"date":"2025-04-17","current":-2.087333,"twenty":-5.772137,"median":-4.943869,"eighty":-4.262226,"marketCap":161717306.12},{"date":"2025-04-25","current":-1.989924,"twenty":-5.763976,"median":-4.926712,"eighty":-4.244659,"marketCap":153942927.22},{"date":"2025-05-02","current":-2.118643,"twenty":-5.749551,"median":-4.912127,"eighty":-4.234462,"marketCap":162773354.76},{"date":"2025-05-06","current":-2.09777,"twenty":-5.745151,"median":-4.91141,"eighty":-4.22993,"marketCap":162193904.9}],"updateTime":1746680501090}}}